Tau Propagation Causality Test — Does Tau Spread Drive Neurodegeneration or Is It a Bystander?
📖 Wiki Page
experiment653 wordssynced 2026-04-02
Tau Propagation Causality Test
Overview
This experiment addresses the critical AD knowledge gap: "Does tau spread cause neurodegeneration or is it a bystander?" (ranked #5 in AD Knowledge Gaps with 30 points). This question determines whether anti-tau therapies will be curative or only symptomatic.
Key Question
Is the correlation between tau propagation and cognitive decline causal? Does stopping tau spread necessarily halt neurodegeneration, or can tau spread independently without causing neuronal loss?
Study Design
Rationale
If tau spread is causal: preventing propagation should halt neurodegeneration. If tau spread is a bystander: preventing propagation may not affect outcomes — need to target upstream triggers.
Multi-arm Intervention Study
Recruit early AD patients (n=300) with varying baseline tau burden and randomize to:
| Arm | Intervention | Target | |-----|--------------|--------| | 1 | Anti-tau antibody (gosuranemab) | Extracellular tau clearance | | 2 | Tau ASO (BIIB080) | Intracellular tau reduction | | 3 | Tau aggregation inhibitor | Intracellular aggregation block | | 4 | Standard of care | Control |
Primary Endpoints
Tau spread rate: Change in tau PET SUVR over 24 months
This experiment addresses the critical AD knowledge gap: "Does tau spread cause Neurodegeneration or is it a bystander?" (ranked #5 in AD Knowledge Gaps with 30 points). This question determines whether anti-tau therapies will be curative or only symptomatic.
Key Question
Is the correlation between tau propagation and cognitive decline causal? Does stopping tau spread necessarily halt neurodegeneration, or can tau spread independently without causing neuronal loss?
Study Design
Rationale
If tau spread is causal: preventing propagation should halt neurodegeneration. If tau spread is a bystander: preventing propagation may not affect outcomes — need to target upstream triggers.
Multi-arm Intervention Study
Recruit early AD patients (n=300) with varying baseline tau burden and randomize to:
| Arm | Intervention | Target | |-----|--------------|--------| | 1 | Anti-tau antibody (gosuranemab) | Extracellular tau clearance | | 2 | Tau ASO (BIIB080) | Intracellular tau reduction | | 3 | Tau aggregation inhibitor | Intracellular aggregation block | | 4 | Standard of care | Control |
Primary Endpoints
Tau spread rate: Change in tau PET SUVR over 24 months
Granger causality: Does tau PET signal predict future neurodegeneration?
Mediation analysis: Does tau mediate amyloid → cognitive decline?
Intervention contrast: Do different mechanisms of tau reduction differ in neurodegeneration effect?
Expected Outcomes
Hypothesis 1: Tau Spread Is Causal
Anti-tau interventions reduce both tau spread and neurodegeneration
Correlation between tau change and neurodegeneration is maintained across arms
Prediction: Strong correlation (r > 0.6) between tau PET change and cognitive decline
Hypothesis 2: Tau Spread Is Bystander
Anti-tau interventions reduce tau spread but neurodegeneration continues
Dissociation between tau change and cognitive decline
Prediction: Weak or no correlation (r < 0.3) between tau PET change and cognitive decline
Critical Readouts
If correlation breaks: tau is upstream trigger, not downstream effector
If correlation persists: tau is causal driver of neurodegeneration
Feasibility Assessment
| Factor | Assessment | |--------|------------| | Technical Feasibility | High — tau PET, ASO, antibodies all available | | Recruitment Feasibility | Moderate — requires early AD with low tau burden | | Cost Estimate | $45-60M over 4 years | | Timeline | 48 months | | Cross-Disease Value | Critical — informs all tauopathy therapeutic strategies |